Huaxi Biologics: China Life Chengda, a subsidiary of Chinese Life, intends to reduce its stake in the company by no more than 2.5%.
DATE:  Oct 08 2024

Bloomage Biotech IC data map

Bloomage Biotech's second largest shareholder, China Life Chengda, plans to reduce its holdings.

On the evening of October 8, Bloomage Biotechnology Co., Ltd. (Bloomage Biotech, 688363.SH) issued an announcement on the shareholding reduction plan of shareholders. The announcement pointed out that China Life Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership) (hereinafter referred to as "China Life Chengda") plans to reduce its holdings of the company's shares by centralized bidding and block trading according to market conditions not more than 12,041,955 shares, and the number of shares to be reduced accounts for no more than 2.5% of the company's total share capital, of which the proportion of reduction by centralized bidding does not exceed 1%. The number of shares to be reduced shall not exceed 4,816,782 shares, and the proportion of shares to be reduced by block trading shall not exceed 1.50%, and the number of shares to be reduced shall not exceed 7,225,173 shares, and the reduction period shall be within 3 months after the 15 trading days disclosed in this announcement, that is, from October 31, 2024 to January 28, 2025. If there are changes in the company's shares such as giving away shares, converting to share capital, allotment, repurchase and cancellation during the planned reduction period, the number of the above-mentioned shares will be adjusted accordingly, and the reduction ratio will remain unchanged.

As of the disclosure date of this announcement, the number of shares directly held by China Life Chengda was 34,433,286 shares, accounting for 7.15% of the company's total share capital. The above shares are all pre-IPO shares of the Company and have been listed and circulated since November 7, 2022.

According to Bloomage Biotech's semi-annual report, China Life Chengda is the second largest shareholder of Bloomage Biotech, and China Life Chengda has not reduced its shareholding since the company's listing.

According to industrial and commercial information, China Life Chengda is an investment company under Chinese Life Insurance (Group) Company, and Chinese Life Insurance Co., Ltd. holds 74.9376% of the shares.

The announcement pointed out that China Life Chengda will decide whether to implement the share reduction plan and the progress of the implementation according to factors such as the stock market situation, and there is uncertainty about whether the shareholding reduction plan can be implemented on schedule. The implementation of the shareholding reduction plan will not lead to the risk of a change in control of the listed company.

According to the official website, Bloomage Biotech (688363. Founded in 2000, SH is a world-renowned biotechnology and biomaterials company. Bloomage Biotech mainly focuses on the development and industrial application of bioactives that are conducive to life and health, such as functional sugars, proteins, peptides, amino acids, nucleotides, and natural active compounds. As a platform-based enterprise of the whole biotechnology industry chain, the company's business currently covers bioactive raw materials, medical terminal products, and consumer terminal products (functional skin care products and functional foods). The company is the world's largest hyaluronic acid R&D, production and sales enterprise, and the industrialization level of hyaluronic acid ranks first in the world.

According to Bloomage Biotech's 2024 semi-annual report, the company achieved operating income of 2.811 billion yuan in the first half of the year, a year-on-year decrease of 8.61%; net profit attributable to shareholders of listed companies was 342 million yuan, a year-on-year decrease of 19.51%. The semi-annual report pointed out that the company's overall operating results were under pressure in the first half of the year, mainly due to the fact that management changes generated a series of expenses in the short term, affecting short-term profits and losses; Long-term and strategic investment in R&D and innovation business has not been reduced, and it has continued to grow; Some businesses, such as the functional skin care products business, were in the deep water area of management change during the reporting period, and the market expansion could not be fully developed, achieving revenue of 1.381 billion yuan, a year-on-year decrease of 29.74%. However, from a longer-term perspective, this management change is a strategic and active adjustment after the company's long-term sustained growth.

As of the close of trading on October 8, Bloomage Biotech reported 80.45 yuan / share, up 14.11%.

Follow Yicai Global on

star50stocks

Ticker Name

Percentage Change

Inclusion Date